WPRIM Management System> DCMS> Journal of Gynecologic Oncology> 2012> 23> 1

Volume: 23 Issue: 1

1. Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease. Page:11—15
2. Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media. Page:5—10
3. 9th Korea-Japan Gynecologic Cancer Joint Meeting. Page:3—4
4. The Journal of Gynecologic Oncology and the Asian Society of Gynecologic Oncology: the history, the present and the future. Page:1—2
5. Hereditary portion as an initial genetic approach in gynecologic cancer: synchronous tumor of ovary and endometrium. Page:72—73
6. Late presentation of metastatic smooth muscle neoplasm of the uterus with low malignant potential. Page:69—71
7. Complete biologic response to taxane based chemotherapy confirmed by 18FFDG PET/CT and surgery in a cancer of unknown primary site. Page:65—68
8. Major clinical research advances in gynecologic cancer in 2011. Page:53—64
9. Gastrointestinal stromal tumors as an incidental finding in patients with a presumptive diagnosis of ovarian cancer. Page:48—52
10. Characteristics of thyroid incidentalomas detected by pre-treatment 18FFDG PET or PET/CT in patients with cervical cancer. Page:43—47
11. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Page:35—42
12. Preoperative 18FFDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. Page:28—34
13. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. Page:22—27
14. Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009. Page:16—21

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.